uromitexan 400 mg
megapharm ltd - mesna - solution for injection - mesna 400 mg/vial - mesna - prevention of urinary passage toxicity of oxazaphosphorines (ifosfamide ,cyclophosphamide, trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous ifosfamide, cyclophosphamide or trofosamide , urinary passage diseases in anamnesis.
endoxana coated tablets 50 mg
baxter holding b.v. - cyclophosphamide monohydrate - coated tablet - 50 milligram(s) - nitrogen mustard analogues; cyclophosphamide
endoxana 50mg coated tablets
baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - cyclophosphamide - coated tablet - cyclophosphamide 50 mg - antineoplastic agents
endoxana
baxter healthcare limited - cyclophosphamide monohydrate - coated tablets - 50 milligram - cyclophosphamide
endoxan-asta
baxter healthcare ltd - cyclophosphamide monohydrate 100mg - powder for injection - 100 mg - active: cyclophosphamide monohydrate 100mg excipient: mannitol
endoxan-asta
baxter healthcare ltd - cyclophosphamide monohydrate 213.8mg equivalent to 200 mg cyclophosphamide anhydrous. - powder for injection - 200 mg - active: cyclophosphamide monohydrate 213.8mg equivalent to 200 mg cyclophosphamide anhydrous.
endoxan 500mg powder for injection iv
baxter healthcare phils inc - cyclophosphamide monohydrate - powder for injection iv - 500mg
endoxan 1g powder for injection iv
baxter healthcare phils inc - cyclophosphamide monohydrate - powder for injection iv - 1g
uromitexan
baxter healthcare limited - mesna - solution for inj/inf - 100 mg/ml - mesna
endoxana 50mg tablets
baxter healthcare ltd - cyclophosphamide monohydrate - oral tablet - 50mg